The Company ended 2023 with $15.7 million in cash, investments and accrued interest receivable. Along with future planned sales of the Company’s remaining $1.3 million of New Jersey NOLs, the Company believes it has sufficient capital resources to fund its operations into the fourth quarter of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- IMNN Upcoming Earnings Report: What to Expect?
- Imunon receives $1.3M from sale of New Jersey NOLs
- IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
- IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
- Imunon timelines unchanged despite CEO departure, says H.C. Wainwright
